Serum IL-18 as a Predictive Biomarker for Systemic Inflammation in XIAP Deficiency: A Retrospective Analysis
Journal of Human Immunity · 01.05.2026 · 2 (CIS2026)
DOI: 10.70962/cis2026abstract.186 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Human Immunity, online erschienen am 01.05.2026. Verfasst von Bridget Forde und 5 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
X-linked inhibitor of apoptosis protein (XIAP) deficiency is a rare genetic disorder caused by pathogenic variants in the XIAP gene. It disrupts TNF-receptor signaling and NLRP3 inflammasome function, leading to chronically elevated interleukin-18 (IL-18). Patients present with diverse phenotypes and are predisposed to inflammatory complications such as hemophagocytic lymphohistiocytosis (HLH) and inflammatory bowel disease (IBD). A threshold for symptomatology based on IL-18 levels is unknown.
Methods
We retrospectively analyzed confirmed XIAP-deficient patients to evaluate the relationship between serum IL-18 levels and clinical status. IL-18 measurements were paired with contemporaneous clinical presentations, categorized as either clinically well (no active disease), as having systemic inflammation characterized by fever and/or cytopenia with or without other symptoms of HLH or infection, or as having active IBD. Receiver operating characteristic (ROC) curves were generated to evaluate the predictive value of IL-18 for systemic inflammation and IBD.
Results
Figure 1 presents the ROC curves derived from 26 XIAP-deficient patients (n = 122 samples). IL-18 levels demonstrated poor correlation with IBD. ROC analysis demonstrated that an IL-18 cutoff of 5,000 pg/mL yielded 100% sensitivity and 95% specificity for identifying patients with systemic inflammation. Figure 1.
Conclusion
Serum IL-18 levels greater than 5,000 pg/mL strongly correlate with systemic inflammation in XIAP-deficient patients, suggesting IL-18 as a robust biomarker for risk of systemic inflammatory disease. Incorporating IL-18 measurements into clinical evaluation may improve early detection and prevention of complications of systemic inflammation in this population.
Zitieren
APA
Forde, B., Han, I., Bleesing, J., Ibrahimova, A., Marsh, R., & Chiang, S. (2026). Serum IL-18 as a Predictive Biomarker for Systemic Inflammation in XIAP Deficiency: A Retrospective Analysis. Journal of Human Immunity, 2(CIS2026). https://doi.org/10.70962/cis2026abstract.186
Vancouver
Forde B, Han I, Bleesing J, Ibrahimova A, Marsh R, Chiang S. Serum IL-18 as a Predictive Biomarker for Systemic Inflammation in XIAP Deficiency: A Retrospective Analysis. Journal of Human Immunity. 2026;2(CIS2026). doi:10.70962/cis2026abstract.186
BibTeX
@article{Forde2026,
author = {Forde, Bridget and Han, Ivy and Bleesing, Jack and Ibrahimova, Azada and Marsh, Rebecca and Chiang, Sam},
title = {Serum IL-18 as a Predictive Biomarker for Systemic Inflammation in XIAP Deficiency: A Retrospective Analysis},
journal = {Journal of Human Immunity},
year = {2026},
volume = {2},
number = {CIS2026},
doi = {10.70962/cis2026abstract.186}
}
EUVIMED